Dianthus Therapeutics (NASDAQ:DNTH) Director Sells 7,750 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Anne Mcgeorge sold 7,750 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the transaction, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded down $3.31 during mid-day trading on Tuesday, reaching $108.49. 777,875 shares of the company’s stock were exchanged, compared to its average volume of 972,407. The company’s 50-day moving average is $95.17 and its 200-day moving average is $81.36. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $19.00 and a 52-week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright lifted their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Dianthus Therapeutics in the second quarter worth approximately $401,990,000. Vestal Point Capital LP increased its position in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC raised its holdings in shares of Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.